🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. John Sargent says AI’s early wins will come from easing clinician workload—think #Transcription, navigation, & communication. Clinical decision support is on the horizon. bit.ly/4j9Df8o #COA2025 #Oncology #HealthTech #AIinMedicine #AI BroadReach

New ADC for #NSCLC: Telisotuzumab vedotin earns FDA nod for c-Met+ advanced NSCLC. A first-in-class antibody-drug conjugate, it’s a breakthrough for patients with limited options. bit.ly/4kmrMDA #OncologyNews #ADCs #PrecisionMedicine UCLA

“CMS cuts have reduced the physician fee schedule by 25%—without adjusting for inflation,” says Dr. Casey Chollet-Lipscomb. With rising costs & hypofractionation, the field needs payment reform. Tap for more: bit.ly/4de3xFk #RadOnc #ROCRAct TennesseeOncology

Multiple Myeloma at #ASCO25: Trispecific antibodies like JNJ-79635322 may define the next wave of immune therapy. Early days—but the potential is real. bit.ly/3SKkGN9 #MultipleMyeloma #CarTCellTherapy #MMSM #Immunotherapy Huntsman Cancer Institute Brandon Blue, MD

ODAC votes 8–1 against using #Glofitamab for US #Lymphoma patients, citing #STARGLO trial’s lack of applicability. Only 25 U.S. patients enrolled. bit.ly/4jhsG2Z #ASCO25 #Oncology #Lymphoma Marty Makary MD, MPH Avera Health Vinay Prasad MD MPH FDA Oncology

#ASCO25 Preview: #GastricCancer Set for a Shift. MATTERHORN’s plenary results & DESTINY-Gastric04 could change or reaffirm 2nd-line standards. “We know it’s positive—the question is how positive?” says Raghav Sundar. bit.ly/3FsMzX0 #Immunotherapy #BreastCancer #MMSM

Despite no FDA-approved drug for LG-IR-#, ODAC voted 5–4 against UGN-102 due to lack of randomized data. “We get so much more from a randomized trial,” said Dr Richard Pazdur. Tap for details: bit.ly/4kBdsqV #BladderCancer #mCRPC Marty Makary MD, MPH FDA Oncology

#CancerResearch in Crisis: Widespread layoffs, halted studies, & hiring freezes are hitting #Oncology hard as NIH funding faces historic cuts. “Progress is on the line,” warns American Cancer Society. bit.ly/43pltrR #CancerResearch #OncologyPolicy Michael Sapienza American Cancer Society Cancer Action Network

“Nobody’s voice is louder than your own.” @AONcology CEO Todd Schonherz urges community oncologists to speak up for their patients & practices in a time of mounting financial & legislative pressure. bit.ly/4jbfnkM #COA2025 #OncologyAdvocacy #CommunityOncology

Major shifts in #LungCancer this week: BeiGene ends its anti-TIGIT antibody program after a failed phase 3 trial, while Amgen’s #Tarlatamab outperforms chemo in #SCLC. Tap for details on the PFS boost seen in #NSCLC with bispecific therapy. bit.ly/45rpYVt Chao Wang

First data from #ASCO25 spotlight significant advancements: a novel maintenance regimen improves survival in extensive-stage #SCLC, AI enhances #HER2 scoring accuracy, & #GLP1 agonists show potential in reducing #Obesity-related cancer risks. bit.ly/4kcbsWe #BreastCancer

Clinical Challenge: Your patient qualifies for a promising trial—until it's frozen mid-study due to federal NIH cuts. What’s your move? ➡️ Cuts = paused innovation = compromised care. bit.ly/3FqXyjP #CancerResearch #NIHfunding #ASCO25 #BreastCancer #DCIS Erin Cobain

“Physicians must take patient care issues to lawmakers—prior auth, #PBMs, step therapy—all of it,” says RN Lisa Poiry. “Nobody tells the story better than you.” bit.ly/3Hj5BzD #OncologyAdvocacy #PBMReform #CancerCare #COA2025 Lisa Poiry American Oncology Network

“Nobody’s voice is louder than your own.” @AONcology CEO Todd Schonherz urges community oncologists to speak up for their patients & practices in a time of mounting financial & legislative pressure. bit.ly/4jbfnkM #COA2025 #OncologyAdvocacy #CommunityOncology

KEYNOTE-689: Adding #Pembrolizumab before and after surgery significantly improves EFS in resectable LA-HNSCC. A potential new standard of care after 20+ years of stagnation. bit.ly/3RzHOxw #HeadAndNeckCancer #Oncology #AACR25

We’re on the precipice of transformational change,” says COA’s Nick Ferreyros. PBM reform nearly passed in 2023—expect movement in reconciliation or soon after. bit.ly/3YyBr1j #PBMreform #OncologyPolicy #COA2024 Nicolas Ferreyros

Study: ctDNA in HR+ Metastatic Breast Cancer. Acting on #ESR1 mutations detected via #ctDNA before clinical progression may improve outcomes—insights from Drs. Figlin and Gadi." bit.ly/4k7abPB #BreastCancer VK Gadi

FDA approves #Nivolumab + ipilimumab for unresectable/metastatic MSI-H/dMMR #CRC. CHECKMATE-8HW shows median PFS not reached vs. 5.8 mo w/ chemo (HR 0.21, P<.0001). A new frontline standard? bit.ly/429YJNm Pamela Kunz, MD, FASCO

Study: Arkansas Leads Charge on #PBM Reform. Arkansas bans PBM-owned pharmacies & spread pricing—offering a national blueprint to protect #PatientAccess and fair reimbursement. bit.ly/4iQtsUI #COA2025 #PBMReform Frier Levitt Community Oncology Nicolas Ferreyros

#AI, Sage Transparency, & advocacy are shaping the future of #CommunityOncology care—but looming drug pricing changes & research funding cuts demand attention. Susan Sabo-Wagner, MSN, RN, of @AONcology shares insights: bit.ly/4kogzCw #COA2025 #ValueBasedCare